Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers
NCT07079930Phase 1Recruiting
- Sponsor
- Hadassah Medical Organization
- Start
- Dec 2025
- Primary completion
- Nov 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of psilocybin and d-serine in major depressive disorder (MDD) and anxiety disorder (2 arms), sponsored by Hadassah Medical Organization. Primary endpoint: Treatment-Emergent Adverse Events. Started Dec 2025; status: recruiting.
02
Drugs
psilocybind-serine
03
Conditions
major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on NCT07079930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07079930.